GEN Exclusives

More »

GEN News Highlights

More »
May 18, 2009

MorphoSys and Daiichi Sankyo Add Two Targets to Therapeutic Antibody Collaboration

  • Daiichi Sankyo  extended its antibody therapeutics collaboration with MorphoSys  selecting two new antibody targets against which MorphoSys  will generate antibodies using its HuCAL antibody library technology.

    Daiichi Sankyo acquired the targets through its buy out of U3 Pharma last year. Daiichi Sankyo will be responsible for all preclinical and clinical development of the new antibodies, and has worldwide marketing rights to any resulting products. MorphoSys will receive license fees and development-related milestone and royalty payments.

    The companies’ collaboration to develop therapeutic antibodies using MorphoSys’ HuCAL antibody library technology was initiated in 2006, and in 2008 the contracting period was extended by three years to March 2011, giving Daiichi Sankyo the option to develop and commercialize up to six HuCAL-derived therapeutic antibodies. The collaboration now includes four active antibody therapeutics programs.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »